Why veterans’ trauma requires new therapeutic approaches.
National Geographic recently highlighted emerging research on psilocybin-assisted therapy for patients facing advanced cancer and end-of-life distress. The article explores how psychedelic-assisted therapy may help reduce depression, anxiety, and existential suffering when delivered within structured clinical settings.
Sunstone Therapies is working to set the industry standard for high quality training that prepares mental health professionals to work safely, ethically, and effectively in psychedelic therapy research.
Researchers from Sunstone Therapies, Dana-Farber Cancer Institute, Harvard Medical School, and the University of Vermont have published new findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression navigate profound existential challenges.
Fall 2025 At Sunstone Therapies, healing is understood as a journey—one that unfolds with time, trust, and compassionate care. Known […]
Blending Science, Story, and the Human Side of Healing October, 2025 — Sunstone Therapies CEO Dr. Manish Agrawal joined Dan […]
At Sunstone Therapies, we believe healing goes deeper than the surface. While traditional oncology focuses on physical treatments, many patients still struggle with the psychological and emotional challenges of cancer. Our mission is to address the whole patient, which is why we created the 2Dose Study. This clinical trial, led by Dr. Manish Agrawal, builds on our initial study where 80% of participants experienced a greater than 50% reduction in depressive symptoms. The 2Dose Study will explore whether psilocybin is more effective than an active placebo and if two doses are better than one. The trial is open to people with all stages of cancer, not just advanced disease.
A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.
In psychedelic therapy clinical research, setting clear expectations is paramount. Transparent communication about potential disappointments can significantly reduce anxiety and foster a more grounded, trusting, and ultimately, healing journey for participants.